Strategy

Andrew Parrett argues that strategic partnerships are neither strategic nor are they partnerships. And they don't add value to clinical trial outsourcing.

Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020-just watch out for the harsh light of complacency.

Planning for the long term is increasingly seen as an abstract absurdity. But a lasting business model is still possible-if you learn to adapt.

Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded-and lengthy-race to registration.

In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises-change for pharma is here and its good.

As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.

Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?

Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes.

With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.

Our annual press audit finds that the big news in 2011 for pharma was ... no news.

Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma

Mason Tenaglia offers empirical defense of coupons and copay offset programs.

The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant.

Success in the emerging markets depends significantly on navigating the myths and mental traps.

The time is right for industry to overcome its social media phobia once and for all.

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.

Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.

When it comes to the emerging markets, executing a few key elements of success are more important than ever.

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.